Compare FUTU & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUTU | INCY |
|---|---|---|
| Founded | 2011 | 1991 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1B | 17.0B |
| IPO Year | 2018 | 1994 |
| Metric | FUTU | INCY |
|---|---|---|
| Price | $113.43 | $113.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 28 |
| Target Price | ★ $160.84 | $129.13 |
| AVG Volume (30 Days) | 788.9K | ★ 1.5M |
| Earning Date | 11-17-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | N/A | ★ 1.47 |
| Revenue | N/A | ★ $3,394,635,000.00 |
| Revenue This Year | $20.19 | $15.49 |
| Revenue Next Year | $3.97 | $5.35 |
| P/E Ratio | ★ $17.05 | $76.70 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $80.50 | $82.82 |
| 52 Week High | $202.53 | $132.60 |
| Indicator | FUTU | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 32.66 |
| Support Level | $108.21 | $110.56 |
| Resistance Level | $117.04 | $119.29 |
| Average True Range (ATR) | 3.84 | 3.20 |
| MACD | 0.11 | -1.20 |
| Stochastic Oscillator | 76.21 | 16.85 |
Futu Holdings Ltd is an online broker providing one-stop online investing services.. Through its proprietary digital platforms, Futubull and Moomoo, the Company provides a full range of investment services, including trade execution and clearing, margin financing and securities lending, and wealth management. The Group engages in online brokerage services and margin financing services. It generates its revenue in the form of brokerage commission and handling charge services, and interest income. Geographically, it operates in Hong Kong, which derives key revenue and it also has its presence in other countries.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.